Semaglutide vs. Tirzepatide: How to Choose (2026 Guide)

Semaglutide vs tirzepatide is the comparison most people run into once they start looking at GLP-1 medications for weight management. Both are available as once-weekly injections (Wegovy semaglutide is also approved as a daily tablet), both are FDA-approved under specific brand names, and both were studied in large clinical trials. This guide walks through the difference between semaglutide and tirzepatide so you can have a clearer conversation with a licensed provider.

Key takeaways

• Semaglutide activates 1 hormone receptor (GLP-1); tirzepatide activates 2 (GIP and GLP-1).
• In the SURMOUNT-5 head-to-head trial published in 2025, participants on tirzepatide had a larger average weight reduction than participants on semaglutide. These are study averages; individual results vary.
• The most common side effects are similar for both medications and mostly digestive, and both carry the same boxed warning about thyroid C-cell tumors.
• Wegovy® and Zepbound® are the FDA-approved products for chronic weight management; Ozempic® and Mounjaro® are approved for type 2 diabetes.
• A licensed provider chooses with you based on your health history, goals, tolerance and budget, and a prescription is never guaranteed.

Semaglutide vs tirzepatide: how they work

Both medications are incretin-based therapies. Incretins are gut hormones your body releases after you eat. They help the pancreas release insulin when blood sugar is high, slow how fast the stomach empties, and act on areas of the brain involved in appetite.

Semaglutide is a GLP-1 receptor agonist. It mimics 1 of those hormones, GLP-1, and binds to the same receptors. According to the Wegovy® label, semaglutide decreases calorie intake, likely by affecting appetite.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates the GLP-1 receptor the way semaglutide does, plus a second receptor for a hormone called GIP. The Zepbound® label notes that nonclinical studies suggest GIP may further contribute to the regulation of food intake. This dual mechanism is the core difference between semaglutide and tirzepatide.

Both are commonly used as once-weekly injections under the skin (Wegovy also comes as a once-daily tablet), started at a low dose that a provider increases gradually over several months. Neither replaces nutrition, movement and sleep: both are approved for use together with a reduced-calorie diet and increased physical activity.

Semaglutide vs tirzepatide at a glance

Trial results are averages from specific study populations, not a prediction for you; individual results vary. For prices, see our GLP-1 cost guide.

What the trials showed

Start with the trials behind each approval, then the one trial that tested them head to head.

STEP 1 (semaglutide). Published in the New England Journal of Medicine in 2021, STEP 1 enrolled 1,961 adults with obesity or overweight and without diabetes. Over 68 weeks, the average change in body weight was about -14.9% with the weight-management dose of semaglutide plus lifestyle intervention, compared with about -2.4% on placebo.

SURMOUNT-1 (tirzepatide). Published in the same journal in 2022, SURMOUNT-1 enrolled 2,539 adults with obesity or overweight and without diabetes. Over 72 weeks, the average change in body weight was about -15.0%, -19.5% and -20.9% across the 3 tirzepatide dose levels studied, compared with about -3.1% on placebo.

SURMOUNT-5 (head to head). Comparing 2 separate trials is not a fair test, because populations and designs differ. SURMOUNT-5, published in 2025, randomly assigned 751 adults with obesity and without type 2 diabetes to tirzepatide or semaglutide at the highest dose each person could tolerate. At 72 weeks, the average change in body weight was about -20.2% with tirzepatide and about -13.7% with semaglutide.

Two caveats: SURMOUNT-5 was funded by Eli Lilly and was open-label, and "more on average" does not mean "better for you." An average across hundreds of people does not predict what will happen for any one person.

Side effects: semaglutide vs tirzepatide

The side effect profiles of semaglutide and tirzepatide look more alike than different. Both act on the digestive system, so the most common side effects in the FDA prescribing information for both include nausea, diarrhea, vomiting, constipation, abdominal pain and indigestion. Both labels note that these reactions were reported most often while the dose was being increased. In SURMOUNT-5, the most common adverse events in both groups were gastrointestinal, mostly mild to moderate, and occurred mainly during dose escalation.

In the Wegovy® weight-management trials summarized on its label, about 7% of participants on semaglutide stopped because of side effects, compared with about 3% on placebo. In SURMOUNT-1, about 4% to 7% of participants on tirzepatide stopped because of adverse events, depending on dose, versus about 3% on placebo. These are trial figures, not a prediction for any individual.

Warnings that both medications share

Both carry a boxed warning about a risk of thyroid C-cell tumors, based on rodent studies, and neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Both labels also warn about pancreatitis, gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney injury from dehydration, serious allergic reactions, severe digestive side effects, worsening diabetic eye disease in people with type 2 diabetes, and aspiration during general anesthesia or deep sedation.

In January 2026, the FDA said its evaluation did not identify an increased risk of suicidal thoughts or behavior with GLP-1 medications and asked for that warning to be removed from the labels. The FDA still advises telling your health care professional about new or worsening depression, suicidal thoughts or unusual changes in mood.

When to seek care. Contact your provider right away for severe abdominal pain that does not go away, yellowing of the skin or eyes, vision changes, or signs of low blood sugar (shakiness, sweating, confusion). Call 911 for trouble breathing, swelling of the face or throat, thoughts of harming yourself, or any other emergency. You can report side effects to the FDA MedWatch program at 1-800-FDA-1088.

For more detail, read semaglutide side effects explained and is tirzepatide safe?. Full safety information is on our semaglutide page and tirzepatide page.

Brand names and FDA-approved products

Searches like "Ozempic vs tirzepatide" mix 2 questions: which molecule, and which approved use. The same active ingredient is sold under different brand names for different conditions.

So "Ozempic vs tirzepatide" is really semaglutide vs tirzepatide, with one twist: Ozempic is not FDA-approved for weight management. Wegovy is the semaglutide product indicated for that purpose, and Zepbound is the tirzepatide product. Our Wegovy vs Zepbound comparison goes brand by brand.

Brand names are trademarks of their respective owners; Forever Health Rx is not affiliated with them.

FDA-approved vs compounded

You may see "compounded semaglutide" or "compounded tirzepatide" advertised online. Compounded medications are made by pharmacies rather than by the original manufacturer. They are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are sold. They are not the same as the FDA-approved products Wegovy® and Zepbound®, and they are not "generic" versions of them.

The FDA allowed some compounding while these medications were in shortage. It determined the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. If anyone offers you a compounded product, ask why, ask what is in it, and confirm the pharmacy is licensed in your state.

Cost and access

Cost is often the deciding factor between semaglutide and tirzepatide, and it depends more on your coverage than on the molecule. Manufacturer list prices and self-pay programs change often, so check the manufacturer's own site for the current figure; our GLP-1 cost guide lists the manufacturer prices we could verify, with the date we checked.

Insurance coverage for weight management varies widely. Some plans cover one medication but not the other, some require prior authorization, and some exclude weight-management medications entirely. Coverage can also depend on the reason the medication is prescribed, so ask your plan.

Forever Health Rx pricing, including what each plan includes, is listed on the semaglutide and tirzepatide treatment pages. The online visit is free, and submitting a visit does not guarantee a prescription; that decision belongs to the provider.

Who might be a candidate

Both Wegovy and Zepbound are indicated for adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol, as determined by a licensed provider after reviewing your health history. BMI is a screening measure, not a diagnosis.

Neither medication is appropriate for everyone. They are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, or for people who have had a serious allergic reaction to the medication, and both labels advise stopping treatment when a pregnancy is recognized. A history of pancreatitis or gallbladder disease also needs a careful review.

Read am I a candidate for GLP-1 medication?. When you are ready, you can start your health assessment online.

How a provider chooses with you

There is no universal answer to "which is better." Here is what a licensed provider typically weighs.

1. Your health history. Heart disease, sleep apnea or liver disease may point toward the medication with a matching FDA-approved indication.
2. Prior experience. If you have taken a GLP-1 medication before, how you tolerated it and how you responded matter.
3. Tolerance. The most common side effects are similar for both, but how you handle them in the first weeks can shape the choice.
4. Coverage and budget. The medication your plan covers, or the self-pay price you can sustain, is often the practical choice.
5. Your preferences. Injection versus tablet, pen versus vial, brand familiarity and comfort with a newer option all count.

Switching from semaglutide to tirzepatide (or the other way) is a provider decision. It may come up if you have plateaued, if side effects are hard to manage, or if coverage changes. Never switch, combine or adjust doses on your own.

At Forever Health Rx, this conversation happens during a provider-guided online visit. You share your health history, the provider reviews it and, if appropriate, prescribes the medication they consider the right fit. Learn about semaglutide and tirzepatide, read what happens in your online visit, or start your health assessment.